Giorgio Ottaviani Ph.D.

Giorgio Ottaviani PhD, DABT has extensive work experience in various roles related to preclinical development and pharmaceutical research. Giorgio currently serves as an Operating Partner at Versant Ventures, where they provide expertise and guidance in the development of innovative therapies. Prior to this, they held founding senior leadership positions at Granite Bio, Ridgeline Discovery, Black Diamond Therapeutics, Vertical Bio, Matterhorn Biosciences, Cimeio Therapeutics, Monte Rosa Therapeutics, and Bright Peak Therapeutics. Their roles in these companies involved overseeing preclinical development and contributing to the growth and success of the organizations. Before their roles in the biotech industry, Ottaviani had a significant tenure at Roche, where they held multiple leadership positions, including Global Head of DMPK-PD Project Leaders and Pharmacokinetics and Site Head of Non-Clinical Safety and DMPK at Roche Innovation Center Shanghai. Their experience at Roche involved leading teams and conducting research in areas such as drug metabolism, pharmacokinetics, and non-clinical safety. Ottaviani's strong background in preclinical development and pharmaceutical research make him a valuable asset in the biotech industry.

Giorgio Ottaviani earned a Bachelor's degree in Chemistry from the Università degli Studi di Perugia in 1998. Giorgio then pursued a Visiting Student Erasmus Program in Advanced Organic Chemistry at the Université Grenoble Alpes in 1998. In 1999, they completed a Master's degree in Organic and Computational Chemistry from the Università degli Studi di Perugia. Subsequently, in 2002, they obtained a Master's degree in Science, Technology, and Management from the Università degli Studi di Ferrara. Continuing their education, Ottaviani completed their PhD in Pharmaceutical Sciences from the University of Geneva between 2003 and 2006. In 2016, they achieved the title of Diplomate American Board of Toxicology in General Toxicology from the American Board of Toxicology. Additionally, in December 2022, they obtained the DABT certification from the American Board of Toxicology, Inc.